Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Treating the Transparency Issue of Prescription Costs

Transparency is a word not often associated with the medical industry, particularly as it relates to the patient’s cost for medication. When prescribing drugs for their patients, providers typically do not have access to prescription pricing, nor to information on lower-cost options that may be more in line with a person’s out-of-pocket costs. With 24%…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Transparency is a word not often associated with the medical industry, particularly as it relates to the patient’s cost for medication. When prescribing drugs for their patients, providers typically do not have access to prescription pricing, nor to information on lower-cost options that may be more in line with a person’s out-of-pocket costs. With 24% percent of patients saying they’re not confident that they will be able to afford their medications, this lack of insight at the point-of-care can lead to distrust, affecting both the patient-physician relationship and the patient’s adherence to their treatment plan.

Transparency Means Trust

Most healthcare professionals do not have appropriate access to the data they need to manage drug spending. In fact, in a recent study of more than 500 healthcare professionals, 78% of respondents said they would like to have access to patient out-of-pocket costs. The data also showed that 69% of survey takers find it important to have access to information on low-cost therapeutic alternatives to prescriptions.

This urge for more transparency is a positive sign for provider-patient relationships. When a physician can explain all available options to a patient, there is a much higher likelihood that he or she will take an additional interest in their health overall. When a patient knows what they are paying for, the probability that they will stick with their medication plan increases. Trust will develop because of this clarity, instead of a feeling of deceit.

Better Relationships, Better Work

Automated processes are another way to convey information clearly to patients. This also has the additional benefit of improving clinic employee workflow. The 2018 AMA Prior Authorization Survey revealed that 65% of respondents wait at least one business day for prior authorization outcomes, with 26% waiting at least three business days.

These delays can lead to a direct abandonment of medication plans by patients, and without patient-specific information at the point-of-care, physicians are spending more time on non-clinical and administrative tasks rather than on patient care. This patient-specific data, however, can be placed on Electronic Health Record (EHR) systems, offering patients better price and prescription visibility while allowing physicians more time to focus on the detailed and specific needs of their patients.

EHR and eRx Need to Lead the Way

A trip to the doctor is already unnerving enough for most people; the looming threat of indefinite prescription pricing is another burden altogether. If providers of prescription pills and the pharmacies that sell them worked more in tandem to digitize and make pricing explicitly clear, they would both stand to gain. Further, patients would be more engaged with their treatment plans and stick to them, knowing that they are on the most suitable and affordable medications for their specific needs. Collaboration between EHR and eRx firms can help pave the path to price transparency, connecting pharmacies, physicians and patients together to improve the value of care and the reputation of the medical industry as a whole.

At ChartLogic, we are driven by the desire to improve patient care, office efficiency, and profitability for the physician practice. With that in mind, we will continue to add products and services that help practices improve efficiencies so that healthcare professionals can focus on what matters most: patient care.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512